WO2003020200A8 - A novel pharmaceutical compound and methods of making and using same - Google Patents
A novel pharmaceutical compound and methods of making and using sameInfo
- Publication number
- WO2003020200A8 WO2003020200A8 PCT/US2001/043117 US0143117W WO03020200A8 WO 2003020200 A8 WO2003020200 A8 WO 2003020200A8 US 0143117 W US0143117 W US 0143117W WO 03020200 A8 WO03020200 A8 WO 03020200A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- making
- methods
- same
- pharmaceutical compound
- novel pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003524514A JP2006516947A (en) | 2000-11-16 | 2001-11-16 | Novel pharmaceutical compound and method for producing and using the same |
ES01273387T ES2373641T3 (en) | 2000-11-16 | 2001-11-16 | A NEW PHARMACEUTICAL COMPOUND AND METHODS TO MANUFACTURE AND USE. |
AU2001297565A AU2001297565B2 (en) | 2000-11-16 | 2001-11-16 | A novel pharmaceutical compound and methods of making and using same |
IL15592801A IL155928A0 (en) | 2000-11-16 | 2001-11-16 | A novel pharmaceutical compound and methods of making and using same |
EP01273387A EP1357928B1 (en) | 2000-11-16 | 2001-11-16 | A novel pharmaceutical compound and methods of making and using same |
AT01273387T ATE533512T1 (en) | 2000-11-16 | 2001-11-16 | NOVEL PHARMACEUTICAL COMPOUND AND METHOD FOR THE PRODUCTION AND USE OF THE SAME |
US10/923,088 US7427600B2 (en) | 2000-08-22 | 2004-08-23 | Active agent delivery systems and methods for protecting and administering active agents |
US11/392,878 US20070060500A1 (en) | 2000-08-22 | 2006-03-30 | Pharmaceutical compositions for prevention of overdose or abuse |
Applications Claiming Priority (327)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
USUNKNOWN | 1999-06-07 | ||
US24871300P | 2000-11-16 | 2000-11-16 | |
US24871600P | 2000-11-16 | 2000-11-16 | |
US24874300P | 2000-11-16 | 2000-11-16 | |
US24869900P | 2000-11-16 | 2000-11-16 | |
US24869700P | 2000-11-16 | 2000-11-16 | |
US24859600P | 2000-11-16 | 2000-11-16 | |
US24853700P | 2000-11-16 | 2000-11-16 | |
US24868800P | 2000-11-16 | 2000-11-16 | |
US24872400P | 2000-11-16 | 2000-11-16 | |
US24874600P | 2000-11-16 | 2000-11-16 | |
US24852700P | 2000-11-16 | 2000-11-16 | |
US24872300P | 2000-11-16 | 2000-11-16 | |
US24885200P | 2000-11-16 | 2000-11-16 | |
US24872100P | 2000-11-16 | 2000-11-16 | |
US24870900P | 2000-11-16 | 2000-11-16 | |
US24875600P | 2000-11-16 | 2000-11-16 | |
US24871400P | 2000-11-16 | 2000-11-16 | |
US24860600P | 2000-11-16 | 2000-11-16 | |
US24860700P | 2000-11-16 | 2000-11-16 | |
US24871800P | 2000-11-16 | 2000-11-16 | |
US24870400P | 2000-11-16 | 2000-11-16 | |
US24870100P | 2000-11-16 | 2000-11-16 | |
US24861100P | 2000-11-16 | 2000-11-16 | |
US24853100P | 2000-11-16 | 2000-11-16 | |
US24885100P | 2000-11-16 | 2000-11-16 | |
US24874400P | 2000-11-16 | 2000-11-16 | |
US24860400P | 2000-11-16 | 2000-11-16 | |
US24859400P | 2000-11-16 | 2000-11-16 | |
US24853300P | 2000-11-16 | 2000-11-16 | |
US24870200P | 2000-11-16 | 2000-11-16 | |
US24885500P | 2000-11-16 | 2000-11-16 | |
US24860800P | 2000-11-16 | 2000-11-16 | |
US24870700P | 2000-11-16 | 2000-11-16 | |
US24869600P | 2000-11-16 | 2000-11-16 | |
US24853800P | 2000-11-16 | 2000-11-16 | |
US24859700P | 2000-11-16 | 2000-11-16 | |
US24870600P | 2000-11-16 | 2000-11-16 | |
US24885800P | 2000-11-16 | 2000-11-16 | |
US24869500P | 2000-11-16 | 2000-11-16 | |
US24869800P | 2000-11-16 | 2000-11-16 | |
US24873200P | 2000-11-16 | 2000-11-16 | |
US24872900P | 2000-11-16 | 2000-11-16 | |
US24869400P | 2000-11-16 | 2000-11-16 | |
US24872700P | 2000-11-16 | 2000-11-16 | |
US24872500P | 2000-11-16 | 2000-11-16 | |
US24859500P | 2000-11-16 | 2000-11-16 | |
US24860300P | 2000-11-16 | 2000-11-16 | |
US24872600P | 2000-11-16 | 2000-11-16 | |
US24884900P | 2000-11-16 | 2000-11-16 | |
US24852800P | 2000-11-16 | 2000-11-16 | |
US24885300P | 2000-11-16 | 2000-11-16 | |
US24860900P | 2000-11-16 | 2000-11-16 | |
US24873300P | 2000-11-16 | 2000-11-16 | |
US24853000P | 2000-11-16 | 2000-11-16 | |
US24871200P | 2000-11-16 | 2000-11-16 | |
US24872800P | 2000-11-16 | 2000-11-16 | |
US24885700P | 2000-11-16 | 2000-11-16 | |
US24872200P | 2000-11-16 | 2000-11-16 | |
US24854000P | 2000-11-16 | 2000-11-16 | |
US24871100P | 2000-11-16 | 2000-11-16 | |
US24885600P | 2000-11-16 | 2000-11-16 | |
US24853900P | 2000-11-16 | 2000-11-16 | |
US24853500P | 2000-11-16 | 2000-11-16 | |
US24885000P | 2000-11-16 | 2000-11-16 | |
US24870300P | 2000-11-16 | 2000-11-16 | |
US24873000P | 2000-11-16 | 2000-11-16 | |
US24869200P | 2000-11-16 | 2000-11-16 | |
US24870000P | 2000-11-16 | 2000-11-16 | |
US24859900P | 2000-11-16 | 2000-11-16 | |
US24868600P | 2000-11-16 | 2000-11-16 | |
US24874500P | 2000-11-16 | 2000-11-16 | |
US24853600P | 2000-11-16 | 2000-11-16 | |
US24885400P | 2000-11-16 | 2000-11-16 | |
US24874800P | 2000-11-16 | 2000-11-16 | |
US24859800P | 2000-11-16 | 2000-11-16 | |
US24852600P | 2000-11-16 | 2000-11-16 | |
US24868900P | 2000-11-16 | 2000-11-16 | |
US24860100P | 2000-11-16 | 2000-11-16 | |
US24872000P | 2000-11-16 | 2000-11-16 | |
US24871700P | 2000-11-16 | 2000-11-16 | |
US24869100P | 2000-11-16 | 2000-11-16 | |
US24878900P | 2000-11-16 | 2000-11-16 | |
US24869300P | 2000-11-16 | 2000-11-16 | |
US24853200P | 2000-11-16 | 2000-11-16 | |
US24867000P | 2000-11-16 | 2000-11-16 | |
US24860200P | 2000-11-16 | 2000-11-16 | |
US24871000P | 2000-11-16 | 2000-11-16 | |
US24874700P | 2000-11-16 | 2000-11-16 | |
US24852500P | 2000-11-16 | 2000-11-16 | |
US24852900P | 2000-11-16 | 2000-11-16 | |
US24870800P | 2000-11-16 | 2000-11-16 | |
US24860000P | 2000-11-16 | 2000-11-16 | |
US24871500P | 2000-11-16 | 2000-11-16 | |
US24871900P | 2000-11-16 | 2000-11-16 | |
US24873100P | 2000-11-16 | 2000-11-16 | |
US24870500P | 2000-11-16 | 2000-11-16 | |
US24852400P | 2000-11-16 | 2000-11-16 | |
US60/248,760 | 2000-11-16 | ||
US60/248,532 | 2000-11-16 | ||
US60/248,622 | 2000-11-16 | ||
US60/248,731 | 2000-11-16 | ||
US60/248,699 | 2000-11-16 | ||
US60/248,665 | 2000-11-16 | ||
US60/248,597 | 2000-11-16 | ||
US60/248,856 | 2000-11-16 | ||
US60/248,629 | 2000-11-16 | ||
US60/248,770 | 2000-11-16 | ||
US60/248,594 | 2000-11-16 | ||
US60/248,854 | 2000-11-16 | ||
US60/248,720 | 2000-11-16 | ||
US60/248,721 | 2000-11-16 | ||
US60/248,669 | 2000-11-16 | ||
US60/248,694 | 2000-11-16 | ||
US60/248,737 | 2000-11-16 | ||
US60/248,858 | 2000-11-16 | ||
US60/248,599 | 2000-11-16 | ||
US60/248,692 | 2000-11-16 | ||
US60/248,595 | 2000-11-16 | ||
US60/248,703 | 2000-11-16 | ||
US60/248,609 | 2000-11-16 | ||
US60/248,602 | 2000-11-16 | ||
US60/248,649 | 2000-11-16 | ||
US60/248,778 | 2000-11-16 | ||
US60/248,752 | 2000-11-16 | ||
US60/248,637 | 2000-11-16 | ||
US60/248,616 | 2000-11-16 | ||
US60/248,792 | 2000-11-16 | ||
US60/248,614 | 2000-11-16 | ||
US60/248,651 | 2000-11-16 | ||
US60/248,761 | 2000-11-16 | ||
US60/248,530 | 2000-11-16 | ||
US60/248,753 | 2000-11-16 | ||
US60/248,615 | 2000-11-16 | ||
US60/248,613 | 2000-11-16 | ||
US60/248,668 | 2000-11-16 | ||
US60/248,660 | 2000-11-16 | ||
US60/248,717 | 2000-11-16 | ||
US60/248,785 | 2000-11-16 | ||
US60/248,663 | 2000-11-16 | ||
US60/248,671 | 2000-11-16 | ||
US60/248,682 | 2000-11-16 | ||
US60/248,626 | 2000-11-16 | ||
US60/248,536 | 2000-11-16 | ||
US60/248,659 | 2000-11-16 | ||
US60/248,535 | 2000-11-16 | ||
US60/248,642 | 2000-11-16 | ||
US60/248,619 | 2000-11-16 | ||
US60/248,627 | 2000-11-16 | ||
US60/248,531 | 2000-11-16 | ||
US60/248,625 | 2000-11-16 | ||
US60/248,780 | 2000-11-16 | ||
US60/248,708 | 2000-11-16 | ||
US60/248,618 | 2000-11-16 | ||
US60/248,738 | 2000-11-16 | ||
US60/248,657 | 2000-11-16 | ||
US60/248,724 | 2000-11-16 | ||
US60/248,754 | 2000-11-16 | ||
US60/248,775 | 2000-11-16 | ||
US60/248,601 | 2000-11-16 | ||
US60/248,735 | 2000-11-16 | ||
US60/248,722 | 2000-11-16 | ||
US60/248,782 | 2000-11-16 | ||
US60/248,608 | 2000-11-16 | ||
US60/248,746 | 2000-11-16 | ||
US60/248,704 | 2000-11-16 | ||
US60/248,675 | 2000-11-16 | ||
US60/248,691 | 2000-11-16 | ||
US60/248,848 | 2000-11-16 | ||
US60/248,670 | 2000-11-16 | ||
US60/248,700 | 2000-11-16 | ||
US60/248,672 | 2000-11-16 | ||
US60/248,632 | 2000-11-16 | ||
US60/248,777 | 2000-11-16 | ||
US60/248,650 | 2000-11-16 | ||
US60/248,528 | 2000-11-16 | ||
US60/248,638 | 2000-11-16 | ||
US60/248,715 | 2000-11-16 | ||
US60/248,779 | 2000-11-16 | ||
US60/248,736 | 2000-11-16 | ||
US60/248,662 | 2000-11-16 | ||
US60/248,716 | 2000-11-16 | ||
US60/248,789 | 2000-11-16 | ||
US60/248,757 | 2000-11-16 | ||
US60/248,635 | 2000-11-16 | ||
US60/248,696 | 2000-11-16 | ||
US60/248,833 | 2000-11-16 | ||
US60/248,688 | 2000-11-16 | ||
US60/248,667 | 2000-11-16 | ||
US60/248,851 | 2000-11-16 | ||
US60/248,733 | 2000-11-16 | ||
US60/248,539 | 2000-11-16 | ||
US60/248,712 | 2000-11-16 | ||
US60/248,648 | 2000-11-16 | ||
US60/248,857 | 2000-11-16 | ||
US60/248,655 | 2000-11-16 | ||
US60/248,710 | 2000-11-16 | ||
US60/248,748 | 2000-11-16 | ||
US60/248,695 | 2000-11-16 | ||
US60/248,652 | 2000-11-16 | ||
US60/248,600 | 2000-11-16 | ||
US60/248,793 | 2000-11-16 | ||
US60/248,707 | 2000-11-16 | ||
US60/248,774 | 2000-11-16 | ||
US60/248,742 | 2000-11-16 | ||
US60/248,673 | 2000-11-16 | ||
US60/248,734 | 2000-11-16 | ||
US60/248,607 | 2000-11-16 | ||
US60/248,850 | 2000-11-16 | ||
US60/248,739 | 2000-11-16 | ||
US60/248,537 | 2000-11-16 | ||
US60/248,540 | 2000-11-16 | ||
US60/248,603 | 2000-11-16 | ||
US60/248,643 | 2000-11-16 | ||
US60/248,702 | 2000-11-16 | ||
US60/248,786 | 2000-11-16 | ||
US60/248,646 | 2000-11-16 | ||
US60/248,701 | 2000-11-16 | ||
US60/248,605 | 2000-11-16 | ||
US60/248,796 | 2000-11-16 | ||
US60/248,849 | 2000-11-16 | ||
US60/248,612 | 2000-11-16 | ||
US60/248,621 | 2000-11-16 | ||
US60/248,693 | 2000-11-16 | ||
US60/248,640 | 2000-11-16 | ||
US60/248,689 | 2000-11-16 | ||
US60/248,741 | 2000-11-16 | ||
US60/248,767 | 2000-11-16 | ||
US60/248,772 | 2000-11-16 | ||
US60/248,768 | 2000-11-16 | ||
US60/248,610 | 2000-11-16 | ||
US60/248,606 | 2000-11-16 | ||
US60/248,624 | 2000-11-16 | ||
US60/248,797 | 2000-11-16 | ||
US60/248,763 | 2000-11-16 | ||
US60/248,751 | 2000-11-16 | ||
US60/248,697 | 2000-11-16 | ||
US60/248,744 | 2000-11-16 | ||
US60/248,641 | 2000-11-16 | ||
US60/248,680 | 2000-11-16 | ||
US60/248,794 | 2000-11-16 | ||
US60/248,679 | 2000-11-16 | ||
US60/248,647 | 2000-11-16 | ||
US60/248,623 | 2000-11-16 | ||
US60/248,749 | 2000-11-16 | ||
US60/248,773 | 2000-11-16 | ||
US60/248,633 | 2000-11-16 | ||
US60/248,527 | 2000-11-16 | ||
US60/248,762 | 2000-11-16 | ||
US60/248,787 | 2000-11-16 | ||
US60/248,636 | 2000-11-16 | ||
US60/248,639 | 2000-11-16 | ||
US60/248,723 | 2000-11-16 | ||
US60/248,674 | 2000-11-16 | ||
US60/248,596 | 2000-11-16 | ||
US60/248,611 | 2000-11-16 | ||
US60/248,706 | 2000-11-16 | ||
US60/248,714 | 2000-11-16 | ||
US60/248,729 | 2000-11-16 | ||
US60/248,732 | 2000-11-16 | ||
US60/248,676 | 2000-11-16 | ||
US60/248,853 | 2000-11-16 | ||
US60/248,766 | 2000-11-16 | ||
US60/248,769 | 2000-11-16 | ||
US60/248,783 | 2000-11-16 | ||
US60/248,771 | 2000-11-16 | ||
US60/248,630 | 2000-11-16 | ||
US60/248,795 | 2000-11-16 | ||
US60/248,604 | 2000-11-16 | ||
US60/248,713 | 2000-11-16 | ||
US60/248,617 | 2000-11-16 | ||
US60/248,730 | 2000-11-16 | ||
US60/248,711 | 2000-11-16 | ||
US60/248,728 | 2000-11-16 | ||
US60/248,755 | 2000-11-16 | ||
US60/248,526 | 2000-11-16 | ||
US60/248,759 | 2000-11-16 | ||
US60/248,683 | 2000-11-16 | ||
US60/248,658 | 2000-11-16 | ||
US60/248,685 | 2000-11-16 | ||
US60/248,740 | 2000-11-16 | ||
US60/248,745 | 2000-11-16 | ||
US60/248,718 | 2000-11-16 | ||
US60/248,661 | 2000-11-16 | ||
US60/248,750 | 2000-11-16 | ||
US60/248,719 | 2000-11-16 | ||
US60/248,677 | 2000-11-16 | ||
US60/248,684 | 2000-11-16 | ||
US60/248,765 | 2000-11-16 | ||
US60/248,743 | 2000-11-16 | ||
US60/248,791 | 2000-11-16 | ||
US60/248,620 | 2000-11-16 | ||
US60/248,756 | 2000-11-16 | ||
US60/248,598 | 2000-11-16 | ||
US60/248,678 | 2000-11-16 | ||
US60/248,654 | 2000-11-16 | ||
US60/248,747 | 2000-11-16 | ||
US60/248,656 | 2000-11-16 | ||
US60/248,686 | 2000-11-16 | ||
US60/248,698 | 2000-11-16 | ||
US60/248,852 | 2000-11-16 | ||
US60/248,790 | 2000-11-16 | ||
US60/248,645 | 2000-11-16 | ||
US60/248,764 | 2000-11-16 | ||
US60/248,681 | 2000-11-16 | ||
US60/248,525 | 2000-11-16 | ||
US60/248,529 | 2000-11-16 | ||
US60/248,628 | 2000-11-16 | ||
US60/248,524 | 2000-11-16 | ||
US60/248,727 | 2000-11-16 | ||
US60/248,726 | 2000-11-16 | ||
US60/248,709 | 2000-11-16 | ||
US60/248,666 | 2000-11-16 | ||
US60/248,725 | 2000-11-16 | ||
US60/248,705 | 2000-11-16 | ||
US60/248,533 | 2000-11-16 | ||
US60/248,538 | 2000-11-16 | ||
US60/248,644 | 2000-11-16 | ||
US60/248,784 | 2000-11-16 | ||
US60/248,664 | 2000-11-16 | ||
US60/248,631 | 2000-11-16 | ||
US60/248,634 | 2000-11-16 | ||
US60/248,653 | 2000-11-16 | ||
US60/248,776 | 2000-11-16 | ||
US60/248,855 | 2000-11-16 | ||
US60/248,781 | 2000-11-16 | ||
US60/248,758 | 2000-11-16 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US98807101A Continuation-In-Part | 2000-08-22 | 2001-11-16 | |
PCT/US2001/043115 Continuation-In-Part WO2002051432A1 (en) | 2000-08-22 | 2001-11-16 | A novel pharmaceutical compound and methods of making and using same |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/043089 Continuation-In-Part WO2003034980A2 (en) | 2000-08-22 | 2001-11-14 | A novel pharmaceutical compound containing abacavir sulfate and methods of making and using same |
PCT/US2001/043115 Continuation-In-Part WO2002051432A1 (en) | 2000-08-22 | 2001-11-16 | A novel pharmaceutical compound and methods of making and using same |
US10/156,527 Continuation-In-Part US7060708B2 (en) | 1999-03-10 | 2002-05-29 | Active agent delivery systems and methods for protecting and administering active agents |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003020200A2 WO2003020200A2 (en) | 2003-03-13 |
WO2003020200A3 WO2003020200A3 (en) | 2003-09-12 |
WO2003020200A8 true WO2003020200A8 (en) | 2007-01-18 |
Family
ID=37649252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/043117 WO2003020200A2 (en) | 2000-08-22 | 2001-11-16 | A novel pharmaceutical compound and methods of making and using same |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2008201969A1 (en) |
WO (1) | WO2003020200A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003079972A2 (en) * | 2002-02-22 | 2003-10-02 | New River Parmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US7666445B2 (en) | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
US7375083B2 (en) * | 2003-09-30 | 2008-05-20 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
WO2007011955A2 (en) * | 2005-07-18 | 2007-01-25 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
WO2006019760A1 (en) * | 2004-07-14 | 2006-02-23 | Gpc Biotech Ag | Variable-dose packaging system |
CN1988889A (en) * | 2004-07-22 | 2007-06-27 | 株式会社太平洋 | Sustained-release preparations containing topiramate and the producing method thereof |
ATE555657T1 (en) | 2005-09-29 | 2012-05-15 | Syngenta Participations Ag | FUNGICIDE COMPOSITIONS |
CA2767987A1 (en) | 2009-07-17 | 2011-01-20 | Shire Llc | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CA2941867A1 (en) | 2014-03-14 | 2015-09-17 | Cutispharma, Inc. | Composition and method for vancomycin oral liquid |
EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US9695138B1 (en) | 2016-10-17 | 2017-07-04 | Acenda Pharma, Inc. | Phenothiazine derivatives and methods of use thereof |
DK3678705T3 (en) | 2018-09-14 | 2023-06-26 | Enlitisa Shanghai Pharmaceutical Co Ltd | Conjugates of montelukast and peptides |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
IL107400A0 (en) | 1992-11-10 | 1994-01-25 | Cortech Inc | Bradykinin antagonists |
US6048736A (en) * | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
-
2001
- 2001-11-16 WO PCT/US2001/043117 patent/WO2003020200A2/en active Search and Examination
-
2008
- 2008-05-02 AU AU2008201969A patent/AU2008201969A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2008201969A1 (en) | 2008-05-29 |
WO2003020200A2 (en) | 2003-03-13 |
WO2003020200A3 (en) | 2003-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003020200A8 (en) | A novel pharmaceutical compound and methods of making and using same | |
AU2001263229A1 (en) | Compositions and methods for administration of pharmacologically active compounds | |
AU2002243277A1 (en) | Methods and compositions for encapsulating active agents | |
AU2002235140A1 (en) | Fluidic self-assembly of active antenna | |
WO2003002136A3 (en) | Stable formulation of modified glp-1 | |
WO2000055124A3 (en) | Novel compounds and compositions as protease inhibitors | |
AU2268301A (en) | Novel urea compounds, compositions and methods of use and preparation | |
AU2001234114A1 (en) | Drugs containing combined active ingredients | |
AU2001248215A1 (en) | Cosmetically active composition | |
WO2001007049A3 (en) | Ophthalmic composition comprising ketotifen | |
AU2001239363A1 (en) | Method for fighting against arthropods destructive of crops and composition therefor | |
AU2002327097A1 (en) | Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient | |
AU2003228658A1 (en) | Conjugates of membrane translocating agents and pharmaceutically active agents | |
AU2001268131A1 (en) | Stabilized compositions containing oxygen-labile active agents | |
AU2001286242A1 (en) | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | |
WO2002015933A3 (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
CA2411787A1 (en) | Stable gabapentin having ph within a controlled range | |
AU2001270626A1 (en) | Floating type formulation of agricultural agents | |
PL367957A1 (en) | Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent | |
AU2002316200A1 (en) | Compound and composition for delivering active agents | |
WO2002064093A3 (en) | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation | |
AU2001260089A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
WO2001041734A3 (en) | Stable galenic preparations comprising a benzimidazol and method for the production thereof | |
AU2001277696A1 (en) | Novel physiologically active peptide and use thereof | |
AU2001235976A1 (en) | An antidiabetic composition of amino acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 155928 Country of ref document: IL Ref document number: 2003524514 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2429345 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001273387 Country of ref document: EP Ref document number: 2001297565 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001273387 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |